| furosemide / Generic mfg. |
NCT00151619: Effects of Amlodipine in the Management of Chronic Heart Failure |
|
|
| Terminated | 2 | 7 | Europe | Amlodipine | Rennes University Hospital | Chronic Heart Failure | 09/01 | | | |
NCT00652782: Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients |
|
|
| Completed | 2 | 160 | US | rolofyline, MK7418, Comparator Placebo (unspecified) | NovaCardia, Inc., Merck Sharp & Dohme LLC | Congestive Heart Failure, Renal Impairment | 08/05 | | | |
NCT00283361: ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure |
|
|
| Terminated | 2 | 130 | US | ZP120, I.v. catherization, 6-minutes walk performance, Dyspnea severity assessment, Blood sampling for laboratory tests, ECG, Physical examination | Zealand Pharma, Syneos Health | Heart Failure, Congestive | | 12/06 | | |
NCT00575484: Concentrated Saline Infusions and Increased Dietary Sodium With Diuretics for Heart Failure With Kidney Dysfunction |
|
|
| Terminated | 2 | 11 | US | Hypertonic saline, then oral sodium chloride, Normal saline, then oral placebo capsule | Barnes-Jewish Hospital, Washington University School of Medicine | Congestive Heart Failure, Renal Insufficiency | 07/08 | 07/08 | | |
| Completed | 2 | 33 | US | Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis | Oregon Health and Science University, Pulsion Medical Systems, Oregon Clinical and Translational Research Institute | Acute Lung Injury | 01/11 | 01/11 | | |
NCT01125514 / 2008-006156-22: A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure |
|
|
| Completed | 2 | 37 | Europe | Aliskiren 150 mg, Furosemide 60 mg, Placebo for Aliskiren, Aliskiren 300 mg | Novartis Pharmaceuticals | Heart Failure | 08/11 | 08/11 | | |
| Completed | 2 | 81 | Europe | CLS003, Furosemide, Digoxin, Vehicle topical | Maruho Co., Ltd. | Cutaneous Warts | 08/15 | 08/15 | | |
NCT02821377: Metabolic Effects of Furosemide +HSS in Refractory Ascites |
|
|
| Completed | 2 | 40 | Europe | intravenous furosemide, furosemide +HSS, Hypertonic saline solutions, HSS, Seriated paracentesis, paracentesis | University of Palermo | Ascites, Cirrhosis | 12/15 | 04/16 | | |
NCT02469597: Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis |
|
|
| Completed | 2 | 46 | US | Furosemide, Lasix, Placebo | Northwell Health | Bronchiolitis | 04/16 | 04/16 | | |
| Withdrawn | 2 | 0 | US | Furosemide, Lasix, Placebo, Saline placebo | Loma Linda University | Delayed Graft Function | 10/16 | 10/16 | | |
NCT02501213: Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC) |
|
|
| Terminated | 2 | 14 | Europe | Spironolactone (+/- Furosemide), Spiroctan, Aldactone | Centre Oscar Lambret, National Cancer Institute, France | Cancer | 11/17 | 12/18 | | |
NCT03364842: Furosemide and Coarctation Surgery Lung Complications |
|
|
| Completed | 2 | 56 | RoW | Furosemide | Cairo University | Pulmonary Complication | 12/17 | 12/17 | | |
| Ongoing | 2 | 32 | Europe | Ionic Contra-Viral Therapy (ICVT) comprised of digoxin and furosemide, CLS003, Gel | Cutanea Life Sciences, Cutanea Life Sciences | Actinic keratosis, Actinic keratosis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2016-000870-39: Digoxin / Furosemide topical therapy for genital warts and VIN lesions of immunocompromised and immunocompetent patients |
|
|
| Not yet recruiting | 2 | 48 | Europe | Ionic Contra-Viral Therapy (ICVT) comprised of digoxin and furosemide, CLS003, Gel | Cutanea Life Sciences, Cutanea Life Science | HPV-induced genital lesions of immunocompromised and immunocompetent patients, Genital warts or Vulval HSIL, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT03334240: ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients |
|
|
| Terminated | 2 | 28 | Europe | CLS003, Vehicle | Maruho Co., Ltd. | HPV-Induced Genital Lesions | 10/18 | 10/18 | | |
NCT03684772: Topical Ionic Contra-Viral Therapy in Actinic Keratosis |
|
|
| Unknown status | 2 | 32 | Europe | ICVT Topical Gel, Furosemide Topical Gel, Digoxin Topical Gel, Vehicle Topical Gel | Maruho Co., Ltd. | Actinic Keratosis | 09/19 | 09/19 | | |
NCT02527798: Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD) |
|
|
| Completed | 2 | 82 | US | Furosemide Cohort 1, Lasix, Furosemide Cohort 2, Furosemide Cohort 3, Placebo, sugar water | University of North Carolina, Chapel Hill, Duke University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), The Emmes Company, LLC | Bronchopulmonary Dysplasia | 10/19 | 10/19 | | |
| Completed | 2 | 384 | US | Oral furosemide, Placebo Oral Tablet | University of Pennsylvania | Hypertension, Pregnancy-Induced | 12/19 | 02/20 | | |
NCT03730961: An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic |
|
|
| Completed | 2 | 23 | Europe | BMS-986231, Furosemide, Placebo | Bristol-Myers Squibb | Cardiac Failure, Myocardial Failure, Congestive Heart Failure, Heart Decompensation | 12/19 | 01/20 | | |
2018-000970-31: A study designed to evaluate the effects of BMS-986231 versus placebo on urine output when taken with a single dose of a diuretic (furosemide). BMS-986231 or Placebo are provided in the form of Intravenous Infusions for a duration of 8 hours, with furosemide given after 4 hours, in patients whose heart is unable to pump sufficiently (chronic heart failure); exposed to each of the 2 interventions over the course of the study. |
|
|
| Not yet recruiting | 2 | 20 | Europe | BMS-986231-01 for Injection, 240 mg/vial, BMS-986231, Powder for concentrate for solution for infusion | Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation | Heart failure with reduced ejection fraction (HFrEF), Inability of the heart to pump sufficiently to maintain blood flow to meet the body's needs., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04785755: Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Hepatic Ascites |
|
|
| Completed | 2 | 90 | RoW | Oral standard diuretics therapy, Furosemide (lasix®), Spironolactone (Aldactone®), Hypertonic saline solution, prepared from sodium chloride 0.9% intravenous solution and sodium chloride 3% intravenous solution (, Egypt Otsuka Pharmaceutical Co.)., Etilefrine, (Vascon®) | Hala Abd EL-Tawab Ibrahim Radwan | Hepatic Ascites | 03/20 | 04/20 | | |
NCT04393493: The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide. |
|
|
| Completed | 2 | 80 | RoW | Furosemide intravenous solution, Chlortalidone, Spironolactone | Hospital Civil de Guadalajara | Cardiorenal Syndrome | 04/20 | 04/20 | | |
| Completed | 2 | 482 | Europe, RoW | BAY 1753011, Placebo BAY 1753011, Furosemide, Placebo Furosemide | Bayer | Heart Failure (HF) | 04/21 | 05/21 | | |
NCT04622709: Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis |
|
|
| Completed | 2 | 39 | US | Furosemide (loop diuretic) Tablets | University of North Carolina, Chapel Hill, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Chronic Kidney Disease Requiring Chronic Dialysis | 06/21 | 06/21 | | |
| Terminated | 2 | 51 | US | Nitrates, SL or IV Nitrates, Loop Diuretics, IV Loop Diuretics | Indiana University, Vanderbilt University | Heart Failure, Heart Failure Acute, Acute Cardiac Failure, Acute Cardiac Pulmonary Edema | 12/21 | 12/21 | | |
NCT04919564: Low Dose Continuous Furosemide Effect on Cardiac Surgery Patients With Kidney Dysfunction |
|
|
| Completed | 2 | 90 | RoW | Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL), Lasix injection, NaCl 0.9% | National Cardiovascular Center Harapan Kita Hospital Indonesia | Chronic Kidney Disease, Cardiac Disease | 12/21 | 02/22 | | |
NCT03362515: Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide |
|
|
| Terminated | 2 | 18 | US | Furosemide, Placebo | Thomas Jefferson University | Nasal Polyps | 04/22 | 04/22 | | |
| Withdrawn | 2 | 248 | US | Furosemide, Lasix, Potassium chloride, KCl, Placebo #1, Placebo #2 | Indiana University | Hypertension | 05/22 | 05/22 | | |
NCT04496596: Study of Suramin in Subjects With Furosemide-Resistant AKI |
|
|
| Active, not recruiting | 2 | 68 | US | Suramin, Placebo | Rediscovery Life Sciences | Acute Kidney Injury | 04/23 | 12/23 | | |
NCT05255159: Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors |
|
|
| Recruiting | 2 | 50 | Canada | 18F-DOPA with furosemide | University of Alberta | Neuroendocrine Tumors | 12/24 | 12/24 | | |
| Recruiting | 2 | 60 | RoW | conventional treatment, conventional treatment ( anti diabetic drugs and antihyperlipidimic drugs ), Furosemide or other alternatives , Niaspan or other alternatives, conventional therapy, Trimetazidine, furosemide or other alternative , niaspan or other alternative | October 6 University | Non-Alcoholic Fatty Liver Disease | 06/24 | 09/25 | | |
NCT06036914: A Study of Ultra High Dose Diuretics to Treat Heart Failure |
|
|
| Enrolling by invitation | 2 | 20 | US | Bumetanide, Ultra-high dose diuretic, Furosemide, Standard dose diuretic | Mayo Clinic | Heart Failure; With Decompensation | 08/24 | 08/24 | | |
NCT05779943: Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer |
|
|
| Active, not recruiting | 2 | 20 | US | Furosemide, 54-31-9, FRS, Furosemide, FUROSEMIDE, Lasix, Lasix, LB 502, LB-502, LB-502, SK-Furosemide, F18-rhPSMA-7.3, (18F)-rhPSMA-7.3,18F-rhPSMA-7.3,18FrhPSMA-7.3,2305081-64-3,F-18-rhPSMA-7.3,FLOTUFOLASTAT F-18, Fluorine F18 radiohybrid PSMA-7.3, Fluorine F18 rhPSMA-7.3, Fluorine-18 rhPSMA-7.3, rhPSMA-7.3(18F), Positron Emission Tomography, Medical Imaging,Positron Emission Tomography, PET, PET SCAN, Computed Tomography, CAT, CAT Scan, CAT scan, CAT Scan,Computed Axial Tomography,Computed Tomography, Computerized Axial Tomography | Emory University, National Cancer Institute (NCI), Blue Earth Diagnostics | Prostate Adenocarcinoma, Recurrent Prostate Carcinoma | 07/27 | 07/28 | | |
NCT00982423: The Effects of Decreasing the Lasix Dose on the Cardiorenal System |
|
|
| Completed | 1/2 | 41 | US | Furosemide, Lasix | Mayo Clinic, National Heart, Lung, and Blood Institute (NHLBI) | Heart Failure, Kidney Dysfunction | 07/14 | 07/14 | | |
| Completed | 1/2 | 10 | Europe | Furosemide injection solution for subcutaneous administration (80 mg), Oral Furosemide tablets (80 mg) | scPharmaceuticals, Inc. | Heart Failure | 06/15 | 06/15 | | |
| Completed | 1/2 | 24 | US | Furosemide, Lasix, Saline | Beth Israel Deaconess Medical Center, National Institute of Nursing Research (NINR) | Healthy, Dyspnea | 04/16 | 04/17 | | |
NCT01756677: Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients |
|
|
| Active, not recruiting | 1/2 | 24 | US | Cytarabine, Cytosar, Ara-C, DepoCyt, Cytosine arabinosine hydrochloride, Low dose Ara-C, LDAC, Lintuzumab-Ac225, Lintuzumab, Lasix, furosemide, Spironolactone | M.D. Anderson Cancer Center, Actinium Pharmaceuticals | Leukemia | 10/16 | | | |
|
|
NCT02524054: Aerosol Inhalation Treatment for Dyspnea - Patients |
|
|
| Completed | 1/2 | 24 | US | Furosemide, Lasix, Aerosolized saline, Placebo | Beth Israel Deaconess Medical Center, National Institute of Nursing Research (NINR) | Dyspnea | 11/16 | 12/17 | | |
| Withdrawn | 1/2 | 0 | US | Furosemide Injection Solution 8mg/mL, SCP-101, Buffered Lasix, Buffered furosemide | Todd M Koelling, MD, scPharmaceuticals, Inc. | Acute Decompensated Heart Failure | 03/17 | 03/17 | | |
NCT02575963: Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients |
|
|
| Completed | 1/2 | 40 | US | Cytarabine (Phase 1 only), Low dose Ara-C, LDAC, Lintuzumab-Ac225, HuM195-Ac225, Actimab-A, Furosemide (Phase 1 only), Lasix, Spironolactone, Aldactone | Actinium Pharmaceuticals | AML | 11/18 | 05/20 | | |
|
|
|
NCT04384653: Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure |
|
|
| Completed | 1/2 | 20 | US | Furosemide Injection Solution for subcutaneous administration (80 mg), Furosemide Injection, USP, Medfusion 3500 (v6) precision infusion pump | SQ Innovation, Inc., Accel Clinical Services | Heart Failure | 06/21 | 06/21 | | |
NCT06024889: Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure. |
|
|
| Completed | 1/2 | 20 | Europe | Furosemide Injection | Johannes Grand | Acute Heart Failure | 02/24 | 02/24 | | |
| Recruiting | 1/2 | 20 | US | Furosemide 40 mg, Lasix | Vanderbilt University Medical Center | High Blood Pressure, Salt; Excess, Inflammation | 09/25 | 09/25 | | |
| Not yet recruiting | 1/2 | 84 | Europe | PolyCore (Polydextrin, L-Carnitine, D-xylitol), PolyCore peritoneal dialysis solution | Iperboreal Pharma Srl | Congestive Heart Failure | 11/25 | 03/26 | | |
